ATR is altered in 3.15% of malignant solid tumor patients [3].

ATR is an inclusion criterion in 30 clinical trials for malignant solid tumor, of which 24 are open and 6 are closed. Of the trials that contain ATR status and malignant solid tumor as inclusion criteria, 12 are phase 1 (9 open), 8 are phase 1/phase 2 (5 open), and 10 are phase 2 (10 open) [4].

ATR is altered in 2.7% of breast carcinoma patients [3].

ATR is an inclusion criterion in 21 clinical trials for breast carcinoma, of which 16 are open and 5 are closed. Of the trials that contain ATR status and breast carcinoma as inclusion criteria, 7 are phase 1 (5 open), 2 are phase 1/phase 2 (1 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [4].

ATR is altered in 2.14% of prostate adenocarcinoma patients [3].

ATR is an inclusion criterion in 17 clinical trials for prostate adenocarcinoma, of which 16 are open and 1 is closed. Of the trials that contain ATR status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 14 are phase 2 (13 open), and 2 are phase 3 (2 open) [4].

ATR is altered in 2.32% of ovarian carcinoma patients [3].

ATR is an inclusion criterion in 15 clinical trials for ovarian carcinoma, of which 10 are open and 5 are closed. Of the trials that contain ATR status and ovarian carcinoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (1 open), 6 are phase 2 (5 open), and 1 is phase 3 (0 open) [4].

ATR is altered in 2.11% of prostate carcinoma patients [3].

ATR is an inclusion criterion in 12 clinical trials for prostate carcinoma, of which 9 are open and 3 are closed. Of the trials that contain ATR status and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (1 open), 5 are phase 2 (4 open), and 1 is phase 3 (1 open) [4].

ATR is altered in 9.09% of primary peritoneal carcinoma patients [3].

ATR is an inclusion criterion in 8 clinical trials for primary peritoneal carcinoma, of which 5 are open and 3 are closed. Of the trials that contain ATR status and primary peritoneal carcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

ATR is an inclusion criterion in 7 clinical trials for fallopian tube carcinoma, of which 4 are open and 3 are closed. Of the trials that contain ATR status and fallopian tube carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (1 open), and 1 is phase 3 (0 open) [4].

ATR is altered in 3.72% of non-small cell lung carcinoma patients [3].

ATR is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain ATR status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

ATR is altered in 1.3% of adenocarcinoma of the gastroesophageal junction patients [3].

ATR is an inclusion criterion in 6 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 5 are open and 1 is closed. Of the trials that contain ATR status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [4].

ATR is altered in 6.64% of melanoma patients [3].

ATR is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain ATR status and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [4].

ATR is altered in 6.78% of small cell lung carcinoma patients [3].

ATR is an inclusion criterion in 5 clinical trials for small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATR status and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (0 open) [4].

ATR is altered in 3.92% of colorectal carcinoma patients [3].

ATR is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ATR status and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

ATR is altered in 1.41% of pancreatic adenocarcinoma patients [3].

ATR is an inclusion criterion in 5 clinical trials for pancreatic adenocarcinoma, of which 4 are open and 1 is closed. Of the trials that contain ATR status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

ATR is altered in 6.78% of endometrial carcinoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for endometrial carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ATR status and endometrial carcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ATR is altered in 5.88% of urothelial carcinoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for urothelial carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 2 (3 open) [4].

ATR is altered in 4.08% of head and neck carcinoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for head and neck carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [4].

ATR is altered in 3.14% of cervical carcinoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ATR is altered in 1.54% of gastric carcinoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for gastric carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

ATR is altered in 1.38% of pancreatic carcinoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for pancreatic carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 2 (2 open) [4].

ATR is altered in 1.26% of soft tissue sarcoma patients [3].

ATR is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ATR is altered in 5.81% of bladder carcinoma patients [3].

ATR is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ATR status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [4].

ATR is altered in 6.04% of head and neck squamous cell carcinoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

ATR is altered in 6.18% of squamous cell lung carcinoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [4].

ATR is altered in 2.97% of esophageal carcinoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ATR is altered in 2.42% of high grade ovarian serous adenocarcinoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for high grade ovarian serous adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

ATR is altered in 1.55% of gastric adenocarcinoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ATR is altered in 1.54% of non-hodgkin lymphoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 1 is open and 1 is closed. Of the trials that contain ATR status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

ATR is altered in 1.61% of osteosarcoma patients [3].

ATR is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain ATR status and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ATR is altered in 0.89% of gastrointestinal stromal tumor patients [3].

ATR is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ATR status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ATR is altered in 14.29% of vaginal carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ATR is altered in 5.92% of bladder urothelial carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 5.93% of esophageal squamous cell carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 6.06% of pancreatic ductal adenocarcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for pancreatic ductal adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and pancreatic ductal adenocarcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

ATR is altered in 5.23% of malignant uterine neoplasm patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 9.52% of penile carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ATR is altered in 3.97% of colorectal adenocarcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 4.02% of anaplastic astrocytoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATR is altered in 3.86% of malignant intestinal neoplasm patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 3.86% of lung carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 3.16% of glioblastoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATR is altered in 3.6% of gallbladder carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 2.62% of esophageal adenocarcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 2.58% of medulloblastoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 2.99% of cancer patients [3].

ATR is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains ATR status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 4.43% of anal carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ATR is altered in 2.44% of malignant central nervous system neoplasm patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant central nervous system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 2.32% of malignant esophagogastric neoplasm patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 2.42% of glioma patients [3].

ATR is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 2.26% of malignant small intestinal neoplasm patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 2.12% of leiomyosarcoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 2.72% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 2.53% of biliary tract carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 2.63% of invasive breast carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and invasive breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 2.39% of malignant ovarian epithelial tumor patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 2.24% of bile duct adenocarcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 2.24% of bile duct carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 2.24% of cholangiocarcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 1.96% of diffuse large B-cell lymphoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 1.66% of rhabdomyosarcoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 1.29% of malignant mesothelioma patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 1.54% of malignant gastric neoplasm patients [3].

ATR is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ATR status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 1.29% of ampulla of vater carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ATR is altered in 1.36% of lymphoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATR is altered in 1.16% of low grade ovarian serous adenocarcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 1.49% of sarcoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ATR is altered in 1.24% of B-cell non-hodgkin lymphoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 0.84% of neuroblastoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 0.67% of Ewing sarcoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 0.58% of clear cell renal cell carcinoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is altered in 0.56% of mantle cell lymphoma patients [3].

ATR is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is altered in 0.98% of multiple myeloma patients [3].

ATR is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ATR is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ATR is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ATR status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].